tiprankstipranks
Trending News
More News >
Shandong Xinhua Pharmaceutical Company Limited Class H (HK:0719)
:0719
Hong Kong Market

Shandong Xinhua Pharmaceutical Company Limited Class H (0719) Financial Statements

Compare
2 Followers

Shandong Xinhua Pharmaceutical Company Limited Class H Financial Overview

Shandong Xinhua Pharmaceutical Company Limited Class H's market cap is currently HK$9.37B. The company's EPS TTM is HK$0.694; its P/E ratio is 8.80; and it has a dividend yield of 4.93%. Shandong Xinhua Pharmaceutical Company Limited Class H is scheduled to report earnings on March 26, 2025, and the estimated EPS forecast is HK$0.19. See an overview of income statement, balance sheet, and cash flow financials.
Dec 24Dec 23Dec 22Dec 21Dec 20
Income Statement
Total Revenue¥ 8.47B¥ 8.10B¥ 7.50B¥ 6.56B¥ 6.01B
Gross Profit¥ 2.04B¥ 2.32B¥ 2.04B¥ 1.77B¥ 1.81B
Operating Income¥ 534.37M¥ 534.58M¥ 476.71M¥ 425.59M¥ 422.49M
EBITDA¥ 1.11B¥ 1.09B¥ 1.01B¥ 840.20M¥ 856.79M
Net Income¥ 470.02M¥ 496.51M¥ 411.06M¥ 348.55M¥ 324.86M
Balance Sheet
Cash & Short-Term Investments¥ 1.25B¥ 918.33M¥ 1.16B¥ 744.66M¥ 855.77M
Total Assets¥ 9.02B¥ 8.29B¥ 8.27B¥ 7.33B¥ 7.09B
Total Debt¥ 1.35B¥ 1.08B¥ 1.38B¥ 1.04B¥ 1.09B
Net Debt¥ 107.78M¥ 166.60M¥ 225.11M¥ 299.09M¥ 231.77M
Total Liabilities¥ 3.80B¥ 3.51B¥ 3.92B¥ 3.68B¥ 3.70B
Stockholders' Equity¥ 4.99B¥ 4.55B¥ 4.13B¥ 3.47B¥ 3.22B
Cash Flow
Free Cash Flow¥ 155.19M-¥ 513.48M¥ 9.89M¥ 140.00M
Operating Cash Flow¥ 367.61M¥ 265.28M¥ 758.24M¥ 259.12M¥ 420.19M
Investing Cash Flow-----
Financing Cash Flow¥ 184.78M¥ -196.11M--¥ 35.04M
Currency in CNY

Shandong Xinhua Pharmaceutical Company Limited Class H Earnings and Revenue History

Shandong Xinhua Pharmaceutical Company Limited Class H Debt to Assets

Shandong Xinhua Pharmaceutical Company Limited Class H Cash Flow

Shandong Xinhua Pharmaceutical Company Limited Class H Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis